MX2013001302A - Chronic lymphocytic leukemia (cll) biomarkers. - Google Patents

Chronic lymphocytic leukemia (cll) biomarkers.

Info

Publication number
MX2013001302A
MX2013001302A MX2013001302A MX2013001302A MX2013001302A MX 2013001302 A MX2013001302 A MX 2013001302A MX 2013001302 A MX2013001302 A MX 2013001302A MX 2013001302 A MX2013001302 A MX 2013001302A MX 2013001302 A MX2013001302 A MX 2013001302A
Authority
MX
Mexico
Prior art keywords
cll
biomarkers
lymphocytic leukemia
chronic lymphocytic
methods
Prior art date
Application number
MX2013001302A
Other languages
Spanish (es)
Inventor
David Dornan
Guillemette Duchateau-Nguyen
Tri Quang Nguyen
Giuseppe Palermo
Martin Weisser
Ru-Fang Yeh
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US37040310P priority Critical
Priority to US201161440162P priority
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to PCT/US2011/046205 priority patent/WO2012018771A1/en
Publication of MX2013001302A publication Critical patent/MX2013001302A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57426Specifically defined cancers leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

The present application describes chronic lymphocytic leukemia (CLL) biomarkers. In particular, the invention concerns miRNA151 3p, miRNA409 3p, PTK2, and/or PI3K as biomarkers for patient selection in CLL, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, and methods of advertising related thereto.
MX2013001302A 2010-08-03 2011-08-02 Chronic lymphocytic leukemia (cll) biomarkers. MX2013001302A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US37040310P true 2010-08-03 2010-08-03
US201161440162P true 2011-02-07 2011-02-07
PCT/US2011/046205 WO2012018771A1 (en) 2010-08-03 2011-08-02 Chronic lymphocytic leukemia (cll) biomarkers

Publications (1)

Publication Number Publication Date
MX2013001302A true MX2013001302A (en) 2013-03-08

Family

ID=45559784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001302A MX2013001302A (en) 2010-08-03 2011-08-02 Chronic lymphocytic leukemia (cll) biomarkers.

Country Status (9)

Country Link
EP (1) EP2600895A1 (en)
JP (1) JP2013541501A (en)
KR (1) KR20130045914A (en)
CN (1) CN103153341B (en)
BR (1) BR112013002535A2 (en)
CA (1) CA2806855A1 (en)
MX (1) MX2013001302A (en)
RU (1) RU2013106216A (en)
WO (1) WO2012018771A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2672640T3 (en) 2003-11-05 2018-06-15 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3883899D1 (en) 1987-03-18 1993-10-14 Medical Research Council Londo Modified antibodies.
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
DE68913658D1 (en) 1988-11-11 1994-04-14 Medical Res Council Cloning of immunoglobulin sequences from the variabelen domains.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment process of variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE69233254D1 (en) 1991-06-14 2004-01-08 Genentech Inc Humanized antibodies heregulin
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69334255D1 (en) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker for cancer and biosynthetic binding protein for it
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2091684T3 (en) 1992-11-13 1996-11-01 Idec Pharma Corp therapeutic application of chimeric antibodies and radiolabeled anti-restricted differentiation antigen of human B lymphocytes for the treatment of lymphoma cells b.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH08511420A (en) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド Anti-body
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (en) 1998-04-02 2008-03-01 Genentech, Inc. Variations of antibodies and their fragments.
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2388893T3 (en) * 1998-08-11 2012-10-19 Biogen Idec Inc. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodies
US7682612B1 (en) * 1998-11-09 2010-03-23 Biogen Idec Inc. Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
PL220113B1 (en) 1999-01-15 2015-08-31 Genentech Inc. Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (FcγR), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (en) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Method for controlling the activity of immunologically functional molecule
JP4668498B2 (en) 1999-10-19 2011-04-13 協和発酵キリン株式会社 Method for producing polypeptide
IL149809D0 (en) 1999-12-15 2002-11-10 Genentech Inc Shotgun scanning, a combinatorial method for mapping functional protein epitopes
DK1242438T3 (en) 1999-12-29 2007-02-12 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ES2639222T3 (en) 2000-10-06 2017-10-25 Kyowa Hakko Kirin Co., Ltd. Cells that produce antibody compositions
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (en) 2000-11-30 2013-06-04 Medarex, Inc. Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
PL217751B1 (en) 2001-08-03 2014-08-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
BR0213761A (en) 2001-10-25 2005-04-12 Genentech Inc Compositions, pharmaceutical preparations, industrial article, method of treatment of mammals, host cell, method for producing a glycoprotein and use of the composition
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN101914158A (en) 2002-02-14 2010-12-15 免疫医疗公司 Anti-cd20 antibodies and fusion proteins thereof and methods of use
JP4628679B2 (en) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Cells in which the activity of a protein involved in GDP-fucose transport is reduced or deleted
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk Drug containing antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
JP4753578B2 (en) 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド Synthetic antibody phage library
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
NZ581541A (en) 2002-10-17 2011-07-29 Genmab As Human monoclonal antibodies against CD20
JP4351674B2 (en) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッドGenentech,Inc. Immunoglobulin variants and their use and use
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
NZ541503A (en) 2003-01-22 2008-09-26 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
US9416187B2 (en) 2003-05-09 2016-08-16 Duke University CD-20 specific antibodies and methods of employing same
AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 binding molecules
US20050079184A1 (en) 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk Fused protein composition
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF a1,6-FUCOSYLTRANSFERASE
ES2672640T3 (en) 2003-11-05 2018-06-15 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
PT1725249E (en) 2003-11-06 2014-04-10 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
DE602005015542D1 (en) 2004-01-12 2009-09-03 Applied Molecular Evolution Variants of fc region
NZ550217A (en) 2004-03-31 2009-11-27 Genentech Inc Humanized anti-TGF-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
RU2412947C2 (en) 2004-09-23 2011-02-27 Дженентек, Инк. Antibodies, constructed on cysteine basis and their conjugates
EP1841454A4 (en) 2005-01-13 2009-07-22 Genentech Inc Treatment method
DOP2006000029A (en) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and use thereof. (Variants of an antibody and uses thereof)
WO2006106959A1 (en) 2005-03-31 2006-10-12 Biomedics Inc. Anti-cd-20 monoclonal antibody
JP2009508467A (en) 2005-05-24 2009-03-05 アベスタゲン リミテッド Methods for generating monoclonal antibodies against CD20 for the treatment of B-cell lymphoma
EP1891113A2 (en) 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
KR101460932B1 (en) 2005-08-26 2014-11-12 로슈 글리카트 아게 Modified antigen binding molecules with altered cell signaling activity
CN101296702B (en) * 2005-09-12 2012-11-28 俄亥俄州立大学研究基金会 Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司;群创光电股份有限公司 Liquid crystal panel drive device and its drive method
BRPI0820407A2 (en) * 2007-11-09 2015-05-26 Novartis Ag Use of anti-cd40 antibodies
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
US8580520B2 (en) * 2008-09-15 2013-11-12 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers

Also Published As

Publication number Publication date
EP2600895A1 (en) 2013-06-12
JP2013541501A (en) 2013-11-14
CA2806855A1 (en) 2012-02-09
BR112013002535A2 (en) 2019-09-24
CN103153341B (en) 2015-05-27
KR20130045914A (en) 2013-05-06
WO2012018771A1 (en) 2012-02-09
RU2013106216A (en) 2014-09-10
CN103153341A (en) 2013-06-12

Similar Documents

Publication Publication Date Title
WO2011113606A8 (en) Anti-infective compounds
BRPI0906549A2 (en) Medical bandages with valves and kits containing them.
MX348575B (en) Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases.
WO2011133875A3 (en) Metalloenzyme inhibitor compounds
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
EA201200793A1 (en) Treatment of genotyped patients with diabetes dpp-4 inhibitors, such as linagliptin
SG175078A1 (en) Bispecific anti-erbb-1/anti-c-met antibodies
WO2011160119A3 (en) Anti-gd2 antibodies
EA201490030A1 (en) Metallic enzyme inhibiting compounds
WO2012027570A4 (en) Dual variable domain immunoglobulins and uses thereof
WO2013151736A3 (en) In vivo production of proteins
SG186875A1 (en) Chimeric clotting factors
SG192489A1 (en) Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
EA201170465A1 (en) Methods of treatment of progressive multiple sclerosis
CR20120510A (en) Derivatives piperidin-4-yl azetidine as inhibitors of JAK1
EA201490052A1 (en) Metallic enzyme inhibiting compounds
WO2012177603A3 (en) Metalloenzyme inhibitor compounds
EA201270100A1 (en) Pyrimidinones as PI3K inhibitors
MX2010011088A (en) Novel compositions and methods for the treatment of immune related diseases.
MX2010010398A (en) Novel solid forms of bendamustine hydrochloride.
SG191639A1 (en) Dual variable domain immunoglobulins and uses thereof
IL229114D0 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
WO2012061558A3 (en) Dual variable domain immunoglobulins and uses thereof
SG175081A1 (en) Bispecific anti-erbb-3/anti-c-met antibodies